B
Beta Bionics
Automated insulin delivery system revolutionizes diabetes management with AI-driven decision-making technology
About Beta Bionics
Beta Bionics has developed the iLet Bionic Pancreas, an innovative insulin delivery system that aims to simplify and improve diabetes management. This groundbreaking device uses artificial intelligence to automatically calculate and administer insulin doses based on real-time glucose data from continuous glucose monitors. The iLet system integrates with popular CGM devices like Dexcom and FreeStyle Libre 3 Plus, learning the user's insulin needs over time. Unlike traditional insulin pumps, the iLet eliminates the need for manual carb counting and correction doses, making diabetes management less burdensome for patients. Beta Bionics recently introduced a color version of the iLet, featuring a brighter display and enhanced user interface. This update improves the visibility of glucose levels, meal announcements, and alerts, further enhancing the user experience. The company's mission is to reduce the cognitive burden of diabetes management while improving overall glycemic control. By automating insulin delivery decisions, the iLet Bionic Pancreas represents a significant step forward in diabetes care technology, potentially improving the quality of life for millions of people living with diabetes.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- Irvine, United States
- Listing
- IPO 2025
- Employees
- 438
- Open positions
- None listed
- Dealroom signal
- 91.3/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Diabetes, Medical Systems, Spinout, Wearable, B Corp, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2c
Latest news
Press, funding announcements and product moves mentioning Beta Bionics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Apr 2026 | $0 | — | JPMorgan Chase & Co | ↗ |
| POST IPO EQUITYOther financing | Apr 2026 | $0 | — | SG Americas Securities | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth |
|---|---|---|
| 2026 | $133M | +32.1% |
| 2025 | $100M | +54.1% |
| 2024 | $65M | +442.5% |
| 2023 | $12M | +5900% |
| 2022 | $200K | — |
Growth signals
Latest recorded traffic for Beta Bionics is 73K monthly website visits, up 4.3% over the last three months. Beta Bionics's team grew 23.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
National Institute of Diabetes and Digestive and Kidney Diseases
Series A1 investor entered at this stage
Eventide Asset Management
Series B and later12 investors entered at this stage
Farallon Capital Management
RTW Investments- SCSoleus Capital
Perceptive Advisors
Omega Funds
Sands Capital Management- APArrowMark Partners
- PIPura Vida Investments
Marshall Wace
Wellington Management
JPMorgan Chase & Co- SSSG Americas Securities
Other known investors1 additional known investor
Boston University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Beta Bionics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Beta Bionics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.